Yale study unlocks secrets of heart failure drug entresto

NCT ID NCT04649229

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at how the heart failure drug Entresto (LCZ696) lowers blood pressure and helps the body get rid of salt. 46 stable heart failure patients took part. Researchers measured blood pressure and urine sodium levels to understand the drug's effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Entresto (LCZ696)

What this could lead to

If successful, this could help doctors understand how Entresto works in the body to lower blood pressure and manage heart failure more effectively.

What could go wrong

This is a small, completed study focused on understanding mechanisms, not on proving a new treatment works. Results may not apply to all heart failure patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Yale New Haven Hospital

    New Haven, Connecticut, 06520, United States